No evidence that severity of stroke in internal carotid occlusion is related to collateral arteries

Citation for published version:

Digital Object Identifier (DOI):
10.1136/jnnp.2005.080978

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Neurology, Neurosurgery & Psychiatry

Publisher Rights Statement:
Copyright © 2006 BMJ Publishing Group

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
PAPER

No evidence that severity of stroke in internal carotid occlusion is related to collateral arteries

G E Mead, J M Wardlaw, S C Lewis, M S Dennis, for the Lothian Stroke Registry Study Group


Background/Aim: The neurological effects of internal carotid artery (ICA) occlusion vary between patients. The authors investigated whether the severity of symptoms in a large group of patients with ipsilateral or/and contralateral ICA occlusion at presentation with ocular or cerebral ischaemic symptoms could be explained by patency of other extra or intracranial arteries to act as collateral pathways.

Methods: The authors prospectively identified all patients (n = 2881) with stroke, cerebral transient ischaemic attack (TIA), retinal artery occlusion (RAO), and amaurosis fugax (AFx) presenting to our hospital over five years, obtained detailed history and examination, and examined the intra and extracranial arteries with carotid Doppler, 195 (9%) had ICA occlusion. Among those patients with cortical events, disease in potential collateral arteries (contralateral ICA, external carotid, ipsilateral or contralateral vertebral or intracranial arteries) was equally distributed among patients with severe and mild ischaemic presenting symptoms.

Conclusion: The authors found no evidence that the clinical presentation associated with an ICA occlusion was related to patency of other extra or intracranial arteries to act as collateral pathways. Further work is required to investigate what determines the clinical effects of ICA occlusion.

METHODS

From November 1994 to April 1999, we prospectively identified all patients (including first and recurrent events) presenting to our stroke service with acute stroke, cerebral transient ischaemic attack (TIA), amaurosis fugax (AFx), and retinal artery occlusion (RAO). We recorded whether there was a history of prior stroke or TIA.

A stroke physician examined the patient as soon as possible following onset of symptoms. Those with acute stroke were classified clinically according to the Oxfordshire Community Stroke Project (OCSP).13 Cerebral TIs were categorised as posterior circulation or anterior circulation, then the anterior circulation TIs were further divided into lacunar or cortical TIs according to the presence or absence of cortical symptoms. RAO was defined as monocular visual loss, partial or complete, lasting more than 24 hours likely to be due to vascular disease of the retina. Brain imaging (CT or MRI) was required to investigate collateral pathways.

Abbreviations: ACA, anterior cerebral artery; ACoA, anterior communicating artery; AFx, amaurosis fugax; CCA, common carotid artery; ECA, external carotid artery; ICA, internal carotid artery; LACI, lacunar infarct; MCA, middle cerebral artery; OCSF, Oxfordshire Community Stroke Project; PCiA, posterior cerebral artery; POCl, posterior circulation infarct; RAO, retinal artery occlusion; TACI, total anterior circulation infarct; TIA, transient ischaemic attack.
MRI) was done in patients with acute stroke, and when clinically indicated in patients with cerebral TIA, RAO, and AFx (for example, in patients with multiple or atypical attacks) immediately after medical assessment, in order to identify those with intracranial haemorrhage and stroke “mimics”. We classified infarct site and size using a validated stroke imaging scoring system.

Patients underwent carotid colour Doppler ultrasound imaging (Acuson 128XP 10V, 7 MHz multifrequency probe (Siemens, Germany)) by a consultant neuroradiologist or an experienced neuroradiographer, blinded, where possible, to the type and the side of clinical symptoms immediately after medical assessment. Presence and severity of stenosis in both ICAs, external carotid arteries (ECAs), and common carotid arteries (CCAs) were measured using velocity criteria and lesion appearance. Complete ICA occlusion was diagnosed if there was no colour flow in the lumen of the vessel and no detectable Doppler signal. Flow direction (orthograde or retrograde) and velocity in the vertebral arteries was also recorded. Occluded vertebral arteries were diagnosed when a clear view of the vertebral canal was obtained but no flow was detected.

The intracranial vessels: A1 segment of the anterior cerebral artery (ACA), anterior communicating artery (ACoA), posterior communicating artery (PCoA), middle cerebral artery (MCA), P1 and P2 segments of posterior cerebral artery, ophthalmic artery, intracranial portion of the ICAs and basilar artery, were examined using colour power transcranial Doppler by the same ultrasonographer at the time of carotid imaging, in as many patients as possible. A 2 MHz probe was used for the trans-temporal and suboccipital approaches and a 7 MHz for the transorbital approach. The ultrasonographer made a diagnosis of “normal”, “reduced but still detectable flow”, “occlusion”, “hyperaemia”, or “focal stenosis” using previously reported criteria.

For patients with cortical brain events (that is, total anterior circulation infarcts, TACIs, partial anterior circulation infarcts, PACIs, and cortical TIAs) and an ipsilateral ICA occlusion, we compared the severity of the clinical syndrome with disease in the other extracranial arteries or patterns of flow in the intracranial circulation. We also sought any association between prior TIA or stroke and the severity of current symptoms using $\chi^2$ tests or $\chi^2$ tests for trend. We performed these analyses in two different ways: firstly, we included those patients with no brain imaging; and then we repeated the analyses after excluding patients with cerebral symptoms (that is, stroke and cortical TIA) and no brain imaging. Here we report results after the exclusion of patients with cerebral symptoms and no brain imaging.

### RESULTS

#### Patients

Between November 1994 to April 1999, 2881 patients with stroke, cerebral TIA, RAO, or AFx were identified, of whom 2292 had CT or MR brain imaging (96% of strokes and 61% of cerebral TIAs). 148 with intracerebral haemorrhage and 336 patients with cerebral symptoms and no brain imaging were excluded. Of the remaining 2397 patients, there were 1713 ischaemic strokes, 401 cerebral TIAs, 193 AFx, and 90 RAO.

Of 2228 patients (93%) with carotid Doppler imaging, 195 (9%) had ICA occlusions (fig 1). Of the 195 patients with ICA occlusions, 146 (75%) had an occlusion ipsilateral to the brain or eye lesion only, 36 (18%) had a contralateral occlusion only, eight had bilateral occlusions; and a further

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>TACI and ipsilateral ICA occlusion (n = 22)</th>
<th>PACI and ipsilateral ICA occlusion (n = 70)</th>
<th>Cortical TIA and ipsilateral ICA occlusion (n = 14)</th>
<th>Other patients with any ICA occlusion (n = 89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contralateral ICA disease &gt;70% stenosis, n (%)</td>
<td>5 (23%)</td>
<td>20 (29%)</td>
<td>5 (36%)</td>
<td>47 (53%)</td>
</tr>
<tr>
<td>Any ipsilateral ECA stenosis, n (%)</td>
<td>10 (45%)</td>
<td>29 (41%)</td>
<td>5 (36%)</td>
<td>42 (47%)</td>
</tr>
<tr>
<td>Any contralateral ECA stenosis, n (%)</td>
<td>7 (32%)</td>
<td>18 (26%)</td>
<td>4 (29%)</td>
<td>36 (40%)</td>
</tr>
<tr>
<td>Ipsilateral vertebral artery occluded or reduced flow, n (%)</td>
<td>1 (5%)</td>
<td>8 (11%)</td>
<td>0 (0%)</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Contralateral vertebral artery occluded or reduced flow, n (%)</td>
<td>1 (5%)</td>
<td>7 (10%)</td>
<td>0 (0%)</td>
<td>2 (2%)</td>
</tr>
</tbody>
</table>

ICA, internal carotid artery; ECA, external carotid artery. 
Ipsilateral vertebral artery is on the same side of the neck as the ipsilateral ICA. 
‘‘Other’’ includes the contralateral occlusions, and the RAO, AFx, LACI, lacunar TIA, POCI, and posterior circulation TIA with ipsilateral occlusions.
five occlusions were identified in patients with midline brain lesions or bilateral lesions.

Most of the 7% who did not have carotid imaging had had severe strokes and did not survive or were too ill to move for imaging. As expected, ipsilateral ICA occlusion was most common in patients with cortical and eye events and in those with severe symptoms (fig 1).

There was a history of previous TIA or stroke in 7/22 TACIs (32%), 35/70 (50%) PACIs, and 8/14 (57%) cortical TIAs, but the difference was not significant ($\chi^2$ p = 0.33)

**Extracranial disease**

Among patients with cortical symptoms (TACI, PACI, and cortical TIA) and ipsilateral ICA occlusion there was no significant difference in the prevalence of contralateral ICA disease ($\chi^2$ for trend p = 0.44), ipsilateral external carotid (ECA) disease ($\chi^2$ for trend p = 0.60), contralateral ECA disease ($\chi^2$ for trend p = 0.80), or contralateral or ipsilateral vertebral abnormalities between the three groups (table 1). We repeated the analyses having excluded patients with previous stroke (that is, those whose ICA occlusion may have been symptomatic at some time in the past) but these data did not change the results (data available on request).

**Collateral flow patterns of intracranial vessels**

We looked for trends in collateral flow patterns (table 2) across patients with cortical symptoms (TACI, PACI, and cortical TIA). There were no trends in the proportions of patients with abnormal flow in the intracranial or ophthalmic artery circulation across the three groups with cortical symptoms. The only hint of a difference was that the ipsilateral MCA flow was more often reduced among the TACI and PACI than the cortical TIA patients, as one would expect soon after stroke, consistent with an MCA occlusion rather than indicating collateral flow. Note that the commonest finding was for potential collateral channels, rather than indicating collateral flow. Note that the

---

**Table 2 Transcranial Doppler data from patients with an ipsilateral internal carotid artery occlusion, divided according to presenting syndromes**

<table>
<thead>
<tr>
<th>Artery</th>
<th>TACI and ipsilateral ICA occlusion (n = 22)</th>
<th>PACI and ipsilateral ICA occlusion (n = 70)</th>
<th>Cortical TIA and ipsilateral ICA occlusion (n = 14)</th>
<th>Other patients with any ICA occlusion (n = 89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients in whom TCD was attempted</td>
<td>19</td>
<td>57</td>
<td>12</td>
<td>74</td>
</tr>
<tr>
<td>Ipsilateral bone window adequate</td>
<td>16</td>
<td>30</td>
<td>8</td>
<td>50</td>
</tr>
<tr>
<td>Basilar artery</td>
<td></td>
<td></td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>15%</td>
<td>50%</td>
</tr>
<tr>
<td>Contralateral ACA (A1 direction)</td>
<td></td>
<td></td>
<td>13%</td>
<td>43%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>9%</td>
<td>56%</td>
</tr>
<tr>
<td>Contralateral MCA</td>
<td></td>
<td></td>
<td>6%</td>
<td>36%</td>
</tr>
<tr>
<td>Abnormal</td>
<td></td>
<td></td>
<td>6%</td>
<td>25%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>3%</td>
<td>10%</td>
</tr>
<tr>
<td>Contralateral PCA (P1 direction)</td>
<td></td>
<td></td>
<td>2%</td>
<td>27%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>3%</td>
<td>13%</td>
</tr>
<tr>
<td>Ipsilateral ophthalmic artery</td>
<td></td>
<td></td>
<td>7%</td>
<td>25%</td>
</tr>
<tr>
<td>Right to left</td>
<td></td>
<td></td>
<td>3%</td>
<td>13%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>2%</td>
<td>13%</td>
</tr>
<tr>
<td>Left to right</td>
<td></td>
<td></td>
<td>4%</td>
<td>22%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>2%</td>
<td>13%</td>
</tr>
<tr>
<td>Contralateral bone window adequate</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Correct</td>
<td></td>
<td></td>
<td>7%</td>
<td>44%</td>
</tr>
<tr>
<td>Contralateral ACA (A1 direction)</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Correct</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Contralateral MCA</td>
<td></td>
<td></td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Contralateral PCA (P1 direction)</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Correct</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Contralateral ophthalmic artery</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Correct</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>AcCoA</td>
<td></td>
<td></td>
<td>6%</td>
<td>21%</td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Contralateral bone window adequate</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
<tr>
<td>Correct</td>
<td></td>
<td></td>
<td>7%</td>
<td>23%</td>
</tr>
</tbody>
</table>

---

**www.jnnp.com**
DISCUSSION

This large study of 2450 patients presenting with new neurological symptoms (ranging from transient symptoms to major disabling stroke) found that in those with ipsilateral ICA occlusion, there was no association between adequacy of potential collateral pathways and the severity of stroke symptoms. Although there is an extensive literature on ICA occlusion, few studies have investigated whether collaterals determine the severity and type of symptoms at the time of ICA occlusion, and most of these were either small and/or recruited patients with TIA or minor strokes.3 5 The strength of our study was that we prospectively studied a large cohort of patients presenting to a broad based hospital stroke service, including a substantial number of patients with severe as well as mild strokes, TIsA, and retinal symptoms. Almost all underwent carotid imaging, and of those with ipsilateral ICA occlusion, most had TCD performed, resulting in a complete data set in the majority of patients.

There were some limitations to our study. Our stroke registry did not include asymptomatic people with an ICA occlusion (who might be expected to have the best collateral flow if our original hypothesis was correct—the registry only recorded patients with symptoms. Also, we could not reliably distinguish ICA occlusion occurring at the time of the patients’ presenting symptoms from those which may have occurred some time previously. However, even if the occlusion were longstanding, one might expect the severity of the presenting symptoms to relate to the adequacy of collaterals and therefore still have expected to observe a relationship between flow in collaterals and severity of symptoms. The group most likely to miss having carotid and transcranial Doppler studies (7% of 2397 patients) were the TACIs or POCIs who were more likely to die or be considered too ill for imaging. However, because we found no association between potential sources of intracranial collateral flow and the different patient groups, the exclusion of these few severe strokes probably did not influence our results. We used ultrasound rather than other imaging techniques because it is non-invasive, quick to perform, far more accessible than any other form of carotid imaging, and tolerated by the majority of patients, even those who are very ill. However, the intracranial vessels may be inaccessible in a substantial number of patients, and pathology in the intracranial internal carotid artery and basilar artery may be insufficiently evaluated by TCD.14 The accuracy of duplex Doppler compared with angiography is high for carotid disease,29 so even if we misclassified a few patients with severe ICA stenosis as ICA occlusion, this would not have affected the overall results. We did not examine cerebral perfusion patterns with PET or perfusion MR as it would not have been practical to perform these in such a large group of patients (including severe strokes) and would have restricted and biased our recruitment.

Therefore we still do not know why some patients with ICA occlusion develop severe stroke symptoms and others remain asymptomatic. The underlying cause of ICA occlusion (that is, cardioembolic or thrombus on atheroma) may influence the clinical effects of ICA occlusion by affecting the rate at which collateral vessels may develop.30 Old cannot be distinguished from new ICA occlusions reliably on Doppler imaging, but the few postmortem studies of patients dying from ischaemic stroke show that the aetiology is generally fresh thrombus on pre-existing atheroma31 21 and sudden embolic occlusion in the neck of a previously normal ICA is unusual. There are some data to support the notion that prior stroke or TIA may protect against the effects of sudden ICA occlusion by “ischaemic pre-conditioning”,22 23 and some that do not.22 Our data provide no conclusive evidence either way. However, if prior TIA and stroke are protective, this could relate to use of antiplatelet drugs rather than changes in cerebrovascular haemodynamics, because patients with previous TIA or minor stroke would be more likely to be taking aspirin at the time of their index stroke.

Further work is required to determine what causes some ICA occlusions to cause severe strokes, but our data suggest that it does not seem to be a simple “plumbing” problem. It might be helpful to develop a technique for distinguishing old from new occlusions. Comparison of symptoms in presumed atherosclerotic occlusion (progressive occlusion, with time to develop collaterals) with presumed cardioembolic occlusion might help to determine whether the collateral vessels are important in determining the clinical effects of occlusion.

ACKNOWLEDGEMENTS

This study was funded by the Chief Scientist Office (Scottish Office) reference K/MRS/50/C2457 and would not have been possible without the hard work of all involved in collecting data including numerous research fellows and radiographers funded by the Wellcome Trust and Medical Research Council. JMW and SCL were funded by the Medical Research Council Clinical Research Initiative in Clinical Neurosciences Grant Numbers G9301951 and G9301975.

Authors’ affiliations
J M Wardlaw, S C Lewis, M S Dennis, Division of Clinical Neurosciences, Western General Hospital, Edinburgh, UK
G E Mead, Department of Clinical and Surgical Sciences (Geriatric Medicine), Royal Infirmary of Edinburgh, Edinburgh, UK

Competing interests: None.

Ethical approval (from Lothian Research Ethics Committee) was obtained for the study.

Membership of the Lothian Stroke Registry Study Group: Carl Counsell (clinical fellow), Richard Davenport (clinical fellow), Lesley Day (study secretary), Martin Dennis (secretary), Philip Hay (clinical fellow), Sheila Grant (data entry), Elena Kovadvia (clinical fellow), Steff Lewis (Statistician), Richard Lindley (clinical fellow), Marian Livingstone (data entry and follow up coordinator) Mike McDowall (Programmer & data manager), Gillian Mead (co-investigator), Sunil Narayan (clinical fellow), Joanna Wardlaw (co-principal investigator & study radiologist), Nic Weir (clinical fellow).

REFERENCES

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking contributors:
- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit www.clinicalevidence.com/ceweb/contribute/index.jsp

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:
- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available.

The Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECOMmissioning@bmjgroup.com.

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10-14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp